Issue 6/2002
Content (15 Articles)
Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer
Ian G Campbell, Simon W Baxter, Diana M Eccles, David YH Choong
Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990–1999
Christina A Clarke, Sally L Glaser, Dee W West, Rochelle R Ereman, Christine A Erdmann, Janice M Barlow, Margaret R Wrensch
The importance of being a myoepithelial cell
Marie-Ange Deugnier, Jérôme Teulière, Marisa M Faraldo, Jean Paul Thiery, Marina A Glukhova
Inhibition of E2-induced expression of BRCA1 by persistent organochlorines
Thomas Rattenborg, Irene Gjermandsen, Eva C Bonefeld-Jørgensen
No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer
Amanda B Spurdle, John L Hopper, Xiaoqing Chen, Margaret RE McCredie, Graham G Giles, Beth Newman, Georgia Chenevix-Trench, KumKum Khanna
Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function
Emma Marshman, Charles H Streuli
Expression and prognostic significance of lysozyme in male breast cancer
Carlos Serra, Francisco Vizoso, Lorena Alonso, Juan C Rodríguez, Luis O González, María Fernández, María L Lamelas, Luis M Sánchez, José L García-Muñiz, Aniceto Baltasar, Justo Medrano
Prolactin signaling and Stat5: going their own separate ways?
Cathrin Brisken, Ayyakkannu Ayyanan, Wolfgang Doppler
Estrogen–progestin replacement therapy: regulatory action needed
Malcolm C Pike, Ronald K Ross
Workshop on The Epidemiology of the ATMGene: Impact on Breast Cancer Risk and Treatment, Present Status and Future Focus, Lillehammer, Norway, 29 June 2002
Jonine L Bernstein, Daniela Seminara, Anne-Lise Børresen-Dale